American Brain Tumor Association
Events Care & Support Donate Tumor Info About Us Home Home

March 2012


Register Now for the 2012 ABTA Patient and Family Conference
National brain tumor experts will discuss the latest brain tumor research trends and findings, new and emerging treatment options, and patient/caregiver quality of life issues at the 2012 ABTA Patient and Family Conference. This annual conference runs from Friday, July 27 through Sunday, July 29 at the Marriot Renaissance Chicago O’Hare Suites Hotel. Sessions will cover topics ranging from tumor-specific workshops and new imaging techniques to caregiving strategies and post-treatment wellness. A series of specialized pediatric-focused sessions will also be offered, as will a pre-conference training track for support group facilitators. During the event, ABTA-funded researchers will present posters detailing the scope and results of their efforts. Space is limited, so early registration is recommended. Click here to register.



Start Spreading the News: Breakthrough for Brain Tumors NYC 5K Run/Walk

BT4BT Splash Page w NYC Date 

You'll want to be a part of the inaugural NYC Breakthrough for Brain Tumors 5K Run/Walk on Saturday, November 10, 2012. The event will take place at Hudson River Park Pier 84, West 44th Street & Hudson River Parkway, New York, NY. Click here to sign up for email notification when registration opens. Registration for our Breakthrough for Brain Tumors 5K Chicago is still open at


Team Breakthrough: Post-Close Bibs are Still Available for Chicago Marathon
The Bank of America Chicago Marathon is sold out, but Team Breakthrough still has post-close bibs available for anyone interested in running with the team. Do not miss out on the opportunity to participate in this world class race while making a difference in the lives of brain tumor patients and their families. You can move further & move forward with Team Breakthrough. Visit or contact Alisha Kassam at or (773) 577-8763.


American Brain Tumor Association Participates in Rare Disease Day
ABTA representatives took part in the Food and Drug Administration’s Rare Disease Patient Advocacy Day on March 1 at the FDA’s offices in Silver Spring, MD.  Participants representing a wide spectrum of rare disease organizations engaged in a day-long dialogue with FDA officials in sessions covering the agency’s role in the development of new drugs, biological products and devices, and discussed efforts currently underway aimed at addressing nationwide cancer drug shortages. 



tab research news

Do Hormonal Differences between Males and Females Impact Tumor Growth and Treatment?
Data from a recently published study, Why Does Jack and Not Jill Break His Crown, illustrates that males have an increased incidence of both primary and metastatic brain tumors, as compared to females. The authors theorize that chromosome-based gene expression differences may occur in the first few days after fertilization, resulting in gender-based biologic differences in cell-signaling and physiology. These observations add to the understanding of survival rate differences and treatment responses for males and females. To read the full article on the differing genetic characteristics in tumor biology between males and females, click here.


Primary Site Medulloblastoma May Be Genetically Different from Metastatic Medulloblastoma
An international team of researchers, including ABTA Scientific Advisor Michael Taylor, MD at the Hospital for Sick Children, conducted a study of the genetic characteristics of primary medulloblastoma tumors and their corresponding metastatic sites. The research, presented in the February 2012 Nature, reports that the medulloblastoma metastases are genetically similar, but may not be identical, to the primary tumor. Since clinical approaches to medulloblastoma largely assume the primary tumor and its metastases are highly similar, researchers can now begin to address how these biologic differences may impact treatment results. The study received partial support through two ABTA Basic Research Fellowships. To read the abstract online, click here.

Gamma Knife Radiosurgery and Outcomes for Skull Base Meningioma
A recent retrospective study of 255 patients with skull base meningioma concluded that stereotactic radiosurgery offers a high rate of tumor control and neurological preservation for patients with skull base meningiomas. The article, "Gamma Knife Surgery for Skull Base Meningioma", published in the March 2012 Journal of Neurosurgery, reports long term clinical outcomes (up to 10 years) for these patients.  Click here to read more.

Cognitive Functions Related to Treatment for Primary CNS Lymphoma (PCNSL)
A recent study of post-treatment neuropsychological evaluations for 50 patients with primary CNS lymphoma revealed that cognitive impairments were less prevalent in PCNSL survivors treated with high dose methotrexate-based chemotherapy alone versus those who received high dose methotrexate-based chemotherapy and whole brain radiation therapy. The research, "Cognitive Functions in Primary CNS Lymphoma After Single or Combined Modality Regimes," in the October 2011 Neuro-Oncology, reported that patients who received the high dose chemotherapy alone had higher scores across all neuropsychological tests including attention, executive function, motor speed, and memory. Mild cognitive changes were consistent with the known neurotoxicity of methotrexate-based chemotherapy treatment, but appeared to have less impact on quality of life than treatment that included whole brain radiotherapy.  For additional study information, click here.


Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to funding brain tumor research. For nearly 40 years, the Chicago-based ABTA has been providing critical funding to researchers working toward breakthroughs in brain tumor diagnosis, treatment and care, and is the only national organization providing comprehensive resources that support the complex needs of brain tumor patients and caregivers.

Make a donation to the American Brain Tumor Association.

This information is provided by the American Brain Tumor Association, 8550 W. Bryn Mawr Ave., Suite 550, Chicago, Illinois, 60631. For more information on the American Brain Tumor Association, call toll-free (866) 659-1030, write, or visit 

"American Brain Tumor Association" and "TrialConnect" are registered trademarks of the American Brain Tumor Association. The ABTA logo, the "Breakthrough for Brain Tumors" name and logo, and the "Team Breakthrough" name and logo are trademarks of the American Brain Tumor Association. All rights reserved.

Update Email Preferences | Forward to a Friend | Unsubscribe
©2012 American Brain Tumor Association

 connections_new.JPG FaceBook trialconnect_icon.JPG Twitter [object Object] 


Having Fun Raising Funds 

Ongoing through March 16, 2012
Maine West School Fundraiser
Des Plaines, IL 
April 14, 2012
Metairie, LA
April 22, 2012
Tuttles Hopkins, MN
April 28, 2012
Woonsocket, RI
May 4, 2012
Park Ridge, IL 
May 12, 2012
Chicago, IL
May 12, 2012
Ypsilanti, MI
May 12, 2012
Spokane, WA
June 2, 2012
Arcadia, CA
June 9, 2012
Carmel, IN
July 7, 2012
Windsor, NY
July 20, 2012
Columbia Station, OH
Interested in
hosting an ABTA event? Contact us at


Discover Community Support with ABTA Connections


ABTA's Connections Online Support Community links patients, families, friends, caregivers and health care professionals with each other for support and inspiration. The online community was created to provide a safe place to visit, join and interact with over 500 members of the brain tumor community nationally and around the world.

Find a Clinical Trial Through TrialConnect
The American Brain Tumor Association offers a service that links brain tumor patients with appropriate clinical trials based on tumor type and treatment history. TrialConnect, a free and confidential service administered by EmergingMed, is offered in English and Spanish. Read more.

Consultation Services
Our Care Consultants provide brain tumor information, support and education for patients, families and health care professionals. Write  
or call our toll-free CareLine at (800) 886-ABTA (2282).


This communication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. The links set out on this communication are provided for your convenience only. The American Brain Tumor Association does not endorse the information contained on the linked websites or individual(s)/companies/institutions operating these websites.